Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2018

03.08.2018 | Clinical Study

One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned?

verfasst von: Dieter Henrik Heiland, Gerrit Haaker, Ralf Watzlawick, Daniel Delev, Waseem Masalha, Pamela Franco, Marcia Machein, Ori Staszewski, Oliver Oelhke, Nils Henrik Nicolay, Oliver Schnell

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults with peak incidence in patients older than 65 years. These patients are mostly underrepresented in clinical trials and often undertreated due to concomitant diseases. Recently, different therapeutic approaches for elderly patients with GBM were discussed. To date, there is no defined standard treatment. The aim of the present study is to evaluate the functional and oncological outcome in surgical treatment of elderly patients.

Materials and methods

A total of 342 elderly patients aged ≥ 65 years were retrospectively analyzed in our neurosurgical center. Surgical therapy, adjuvant treatment, overall survival (OS) and functional outcome using Karnofsky performance scale (KPS) and Neurological assessment of neuro-oncology-score were analyzed.

Results

The median age at GBM diagnosis was 73.4 (IQR 9.28) years. Median overall survival was 7.5 (CI 95% 6.0–9.1) months and median preoperative or postoperative KPS was 80 (IQR 20). Surgical resection was performed in 216 (63.2%) patients, in 125 patients (36.5%) patients a stereotactic biopsy was performed. The median OS was significantly higher in patients with gross total resection (GTR) compared to partial resection and biopsy (10.8 months; CI 95% 9.5–12.3). Patients with combined radio- and chemo-therapy (RCT) showed significant longer OS, particularly MGMT-negative GBM. Higher preoperative KPS was found to be associated with improved overall survival.

Conclusion

GTR and adjuvant combined RCT provides benefits for overall survival in elderly patients. Therapy decision should be made in regard to preoperative functional status instead of biological age.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Young JS, Chmura SJ, Wainwright DA, Yamini B, Peters KB, Lukas RV (2017) Management of glioblastoma in elderly patients. J Neurol Sci 380:250–255CrossRefPubMed Young JS, Chmura SJ, Wainwright DA, Yamini B, Peters KB, Lukas RV (2017) Management of glioblastoma in elderly patients. J Neurol Sci 380:250–255CrossRefPubMed
2.
Zurück zum Zitat Stupp R, Dietrich P-Y, Kraljevic SO et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382CrossRefPubMed Stupp R, Dietrich P-Y, Kraljevic SO et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382CrossRefPubMed
5.
Zurück zum Zitat Minniti G, De Sanctis V, Muni R et al (2009) Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neuro-Oncol 91:95–100CrossRef Minniti G, De Sanctis V, Muni R et al (2009) Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neuro-Oncol 91:95–100CrossRef
7.
Zurück zum Zitat Harris G, Jayamanne D, Wheeler H et al (2017) Survival outcomes of elderly patients with glioblastoma multiforme in their 75th year or older treated with adjuvant therapy. Int J Radiat Oncol Biol Phys 98:802–810CrossRefPubMed Harris G, Jayamanne D, Wheeler H et al (2017) Survival outcomes of elderly patients with glioblastoma multiforme in their 75th year or older treated with adjuvant therapy. Int J Radiat Oncol Biol Phys 98:802–810CrossRefPubMed
9.
Zurück zum Zitat Perry JR, Laperriere N, O’Callaghan CJ et al (2017) Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376:1027–1037CrossRefPubMed Perry JR, Laperriere N, O’Callaghan CJ et al (2017) Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376:1027–1037CrossRefPubMed
11.
Zurück zum Zitat Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972CrossRefPubMed Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972CrossRefPubMed
12.
Zurück zum Zitat Nayak L, Deangelis LM, Brandes AA et al (2017) The neurologic assessment in neuro-oncology (NANO) scale: a tool to assess neurologic function for integration into the response assessment in neuro-oncology (RANO) criteria. Neuro-Oncology 19:625–635CrossRefPubMedPubMedCentral Nayak L, Deangelis LM, Brandes AA et al (2017) The neurologic assessment in neuro-oncology (NANO) scale: a tool to assess neurologic function for integration into the response assessment in neuro-oncology (RANO) criteria. Neuro-Oncology 19:625–635CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Hegi ME, Diserens A-C, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003CrossRefPubMed Hegi ME, Diserens A-C, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003CrossRefPubMed
14.
Zurück zum Zitat Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F, Ermani M (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115:3512–3518CrossRefPubMed Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F, Ermani M (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115:3512–3518CrossRefPubMed
15.
Zurück zum Zitat Malmström A, Grønberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926CrossRefPubMed Malmström A, Grønberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926CrossRefPubMed
16.
Zurück zum Zitat Minniti G, Salvati M, Arcella A, Buttarelli F, D’Elia A, Lanzetta G, Esposito V, Scarpino S, Maurizi Enrici R, Giangaspero F (2011) Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neuro-Oncol 102:311–316CrossRef Minniti G, Salvati M, Arcella A, Buttarelli F, D’Elia A, Lanzetta G, Esposito V, Scarpino S, Maurizi Enrici R, Giangaspero F (2011) Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neuro-Oncol 102:311–316CrossRef
17.
Zurück zum Zitat Reifenberger G, Hentschel B, Felsberg J et al (2012) Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 131:1342–1350CrossRefPubMed Reifenberger G, Hentschel B, Felsberg J et al (2012) Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 131:1342–1350CrossRefPubMed
18.
Zurück zum Zitat Wick W, Platten M, Meisner C et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707–715CrossRefPubMed Wick W, Platten M, Meisner C et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707–715CrossRefPubMed
19.
Zurück zum Zitat Chaichana KLKK, Chaichana KLKK, Olivi A, Weingart JD, Bennett R, Brem H, Quinones-Hinojosa A, Quiñones-Hinojosa A (2011) Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article. J Neurosurg 114:587–594CrossRefPubMed Chaichana KLKK, Chaichana KLKK, Olivi A, Weingart JD, Bennett R, Brem H, Quinones-Hinojosa A, Quiñones-Hinojosa A (2011) Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article. J Neurosurg 114:587–594CrossRefPubMed
21.
Zurück zum Zitat Oszvald Á, Güresir E, Setzer M, Vatter H, Senft C, Seifert V, Franz K (2012) Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age. J Neurosurg 116:357–364CrossRefPubMed Oszvald Á, Güresir E, Setzer M, Vatter H, Senft C, Seifert V, Franz K (2012) Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age. J Neurosurg 116:357–364CrossRefPubMed
22.
Zurück zum Zitat Almenawer SA, Badhiwala JH, Alhazzani W et al (2015) Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis. Neuro-Oncology 17:868–881CrossRefPubMedPubMedCentral Almenawer SA, Badhiwala JH, Alhazzani W et al (2015) Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis. Neuro-Oncology 17:868–881CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Zanello M, Roux A, Ursu R et al (2017) Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment? On the Behalf of the Club de Neuro-Oncologie of the Société Française de Neurochirurgie. J Neuro-Oncol. https://doi.org/10.1007/s11060-017-2573-y CrossRef Zanello M, Roux A, Ursu R et al (2017) Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment? On the Behalf of the Club de Neuro-Oncologie of the Société Française de Neurochirurgie. J Neuro-Oncol. https://​doi.​org/​10.​1007/​s11060-017-2573-y CrossRef
Metadaten
Titel
One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned?
verfasst von
Dieter Henrik Heiland
Gerrit Haaker
Ralf Watzlawick
Daniel Delev
Waseem Masalha
Pamela Franco
Marcia Machein
Ori Staszewski
Oliver Oelhke
Nils Henrik Nicolay
Oliver Schnell
Publikationsdatum
03.08.2018
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2018
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-018-2964-8

Weitere Artikel der Ausgabe 2/2018

Journal of Neuro-Oncology 2/2018 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.